iLite® anti-HER2 ADCC Activity Assay

The launch of iLite Assay Ready Cells for use in anti-HER2 antibody development and manufacturing expands the Euro Diagnostica ADCC product line and continues to showcase the unique set-up of the iLite technology:

iLite® ADCC Target HER2 (+) Assay Ready Cells, are human cells engineered to overexpress HER2 and are optimized to give high sensitivity and specificity when used together with iLite® ADCC Effector (V) Assay Ready Cells.

Since unspecific activation of ADCC can be a confounding factor when performing ADCC assays, the iLite® ADCC Target HER2 (-) Assay Ready Cells, which are depleted of HER2 expression, are also available for use as an internal control.

All three products are combined in the iLite® anti-HER2 ADCC Activity Set. This set of cells enables measurements of an anti-HER2 drug’s ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in a straightforward, sensitive and reproducible manner. 


Example of trastuzumab calibration curve using One Glo™ Luciferase Assay System. Values are shown as mean of triplicate ± SD.